Meeting
2020 Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.
Authors
Di Maria Jiang
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Di Maria Jiang , Bryan Wong , Aaron Richard Hansen , Nazanin Fallah-Rad , Adrian G. Sacher , Tong Zhang , Shamini Selvarajah , Tracy Stockley , Philippe L. Bedard , Srikala S. Sridhar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 198)
Abstract #
198
Poster Bd #
J12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2023 ASCO Genitourinary Cancers Symposium
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal
Poster
2024 ASCO Genitourinary Cancers Symposium
A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.
First Author: Xiao X. Wei
Poster
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
First Author: Alexandra Sokolova